Ocular Therapeutix (OCUL) Receivables (2013 - 2026)

Ocular Therapeutix's Receivables history runs 14 years deep, the most recent figure standing at $24.3 million for Q1 2026.

• In Q1 2026, Receivables fell 3.47% year-over-year to $24.3 million; the TTM figure through Mar 2026 stood at $24.3 million (down 3.47% YoY), while the FY2025 annual figure was $30.6 million, down 5.37% from the prior year.
• Receivables was $24.3 million for Q1 2026 at Ocular Therapeutix, down from $30.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $32.4 million in Q4 2024 to a low of $19.8 million in Q3 2022.
• Historically, Receivables has averaged $26.1 million across 5 years, with a median of $26.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables surged 70.25% in 2022, then decreased 8.98% in 2023.
• A 5-year view of Receivables shows it stood at $21.3 million in 2022, then gained by 22.76% to $26.2 million in 2023, then grew by 23.72% to $32.4 million in 2024, then slipped by 5.37% to $30.6 million in 2025, then fell by 20.56% to $24.3 million in 2026.
• The last three Receivables figures came in at $24.3 million (Q1 2026), $30.6 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.